



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

**Correction to  
Lancet Infect Dis 2022;  
published online July 15.  
[https://doi.org/10.1016/  
S1473-3099\(22\)00345-0](https://doi.org/10.1016/S1473-3099(22)00345-0)**

McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. *Lancet Infect Dis* 2022; published online July 15. [https://doi.org/10.1016/S1473-3099\(22\)00345-0](https://doi.org/10.1016/S1473-3099(22)00345-0)—In this Article, the Summary has been corrected to say that between Dec 31, 2020, and March 16, 2022, 13·2 million vaccine doses were administered in Hong Kong's 7·4-million population. This correction has been made to the online version as of July 28, 2022, and will be made to the printed version.

**Correction to  
Lancet Infect Dis 2022;  
published online July 5.  
[https://doi.org/10.1016/  
S1473-3099\(22\)00416-9](https://doi.org/10.1016/S1473-3099(22)00416-9)**

Herman GA, O'Brien MP, Forleo-Neto E, et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* 2022; published online July 5. [https://doi.org/10.1016/S1473-3099\(22\)00416-9](https://doi.org/10.1016/S1473-3099(22)00416-9)—In this Article, the y-axis values of figure 1 were corrected. This correction has been made to the online version as of July 15, 2022, and will be made to the printed version.

**Correction to  
Lancet Infect Dis 2022;  
22: 438–40**

Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19 vaccine schedules—to mix or not to mix? *Lancet Infect Dis* 2022; 22: 438–40—The appendix of this Comment has been corrected as of July 13, 2022.

**Correction to  
Lancet Infect Dis 2022;  
published online July 5.  
[https://doi.org/10.1016/  
S1473-3099\(22\)00311-5](https://doi.org/10.1016/S1473-3099(22)00311-5)**

Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *Lancet Infect Dis* 2022; published online July 5. [https://doi.org/10.1016/S1473-3099\(22\)00311-5](https://doi.org/10.1016/S1473-3099(22)00311-5)—In this Review, the Search strategy and selection criteria panel was missing. This correction has been made to the online version as of July 12, 2022, and will be made to the printed version.



Published Online  
July 28, 2022  
[https://doi.org/10.1016/  
S1473-3099\(22\)00511-4](https://doi.org/10.1016/S1473-3099(22)00511-4)



Published Online  
July 13, 2022  
[https://doi.org/10.1016/  
S1473-3099\(22\)00441-8](https://doi.org/10.1016/S1473-3099(22)00441-8)



Published Online  
July 12, 2022  
[https://doi.org/10.1016/  
S1473-3099\(22\)00468-6](https://doi.org/10.1016/S1473-3099(22)00468-6)



Published Online  
July 15, 2022  
[https://doi.org/10.1016/  
S1473-3099\(22\)00501-1](https://doi.org/10.1016/S1473-3099(22)00501-1)